Your browser doesn't support javascript.
loading
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Robert, Caroline; Ribas, Antoni; Schachter, Jacob; Arance, Ana; Grob, Jean-Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S; McNeil, Catriona M; Lotem, Michal; Larkin, James M G; Lorigan, Paul; Neyns, Bart; Blank, Christian U; Petrella, Teresa M; Hamid, Omid; Su, Shu-Chih; Krepler, Clemens; Ibrahim, Nageatte; Long, Georgina V.
Afiliação
  • Robert C; Institut de Cancérologie Gustave Roussy, Université Paris-Sud, Villejuif, France. Electronic address: caroline.robert@gustaveroussy.fr.
  • Ribas A; David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Schachter J; Sheba Medical Center at Tel HaShomer, Tel HaShomer, Ramat Gan, Israel.
  • Arance A; Hospital Clinic de Barcelona, Barcelona, Spain.
  • Grob JJ; Aix Marseille Université, Hôpital de la Timone, Marseille, France.
  • Mortier L; Université Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France.
  • Daud A; University of California San Francisco, San Francisco, CA, USA.
  • Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, NSW, Australia.
  • McNeil CM; Chris O'Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown, NSW, Australia.
  • Lotem M; Sharett Institute of Oncology, Hadassah Hebrew Medical Center, Jerusalem, Israel.
  • Larkin JMG; Royal Marsden Hospital, London, UK.
  • Lorigan P; University of Manchester and the Christie NHS Foundation Trust, Manchester, UK.
  • Neyns B; Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Blank CU; Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Petrella TM; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Hamid O; The Angeles Clinic and Research Institute, Los Angeles, CA, USA.
  • Su SC; Merck & Co, Kenilworth, NJ, USA.
  • Krepler C; Merck & Co, Kenilworth, NJ, USA.
  • Ibrahim N; Merck & Co, Kenilworth, NJ, USA.
  • Long GV; Melanoma Institute Australia, University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, NSW, Australia.
Lancet Oncol ; 20(9): 1239-1251, 2019 09.
Article em En | MEDLINE | ID: mdl-31345627
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Ipilimumab / Melanoma Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anticorpos Monoclonais Humanizados / Ipilimumab / Melanoma Idioma: En Ano de publicação: 2019 Tipo de documento: Article